HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

2014595 citationsJournal Articlehybrid Open Access

Authors

Eric Van Cutsem · KU Leuven

Yung‐Jue Bang · Seoul National University

Feng-yi Feng · Peking University Cancer Hospital

Jian Xu · 307th Hospital of Chinese People’s Liberation Army

Keun-Wook Lee · Seoul National University Bundang Hospital

Shunchang Jiao

J. León Chong · Instituto Nacional de Enfermedades Neoplásicas

Abstract

HER2 expression varies by tumor location and type. All patients with advanced gastric or gastroesophageal junction cancer should be tested for HER2 status, preferably using IHC initially. Due to the unique characteristics of gastric cancer, specific testing/scoring guidelines should be adhered to.

Topics & Keywords

Gastric Cancer Management and Outcomes HER2/EGFR in Cancer Research Gastrointestinal Tumor Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gastric Cancer

Volume 18, Issue 3, pp. 476-484

DOI: 10.1007/s10120-014-0402-y

Field-Weighted Citation Impact: 19.59